Evidence map›Paper›PMID 32399910›Full record

ArticleCell biology and toxicology2021

Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer.

Ziliang Wang, Yufei Yang, Shuang Hu, Jian He, Zheng Wu, Zihao Qi, Mingzhu Huang, Rujiao Liu, Ying Lin, Cong Tan and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biology and toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. A network map of macrophage-stimulating protein (MSP) signaling.Journal of cell communication and signaling · 2023
    Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ziliang Wang *Department of Medical Oncology and Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. wangziliang@xinhuamed.com.cn.
Yufei Yang *Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shuang Hu *Department of Pharmacy, Eye & Ent Hospital of Fudan University, Shanghai, 200031, China.
Jian HeDepartment of Medical Oncology and Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zheng WuDepartment of Medical Oncology and Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Zihao QiHuadong Hospital Affiliated to Fudan University, Shanghai, 200040, China.
Mingzhu HuangDepartment of Medical Oncology and Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Rujiao LiuDepartment of Medical Oncology and Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Ying LinDepartment of Medical Oncology and Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Cong TanDepartment of Oncology, Shanghai Medical College, Fudan University, 270 Dong'an Road, Shanghai, 200032, China.
Midie XuDepartment of Oncology, Shanghai Medical College, Fudan University, 270 Dong'an Road, Shanghai, 200032, China. xumd27202003@sina.com.
Zhe ZhangDepartment of Medical Oncology and Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. zhangzhe2010fduscc@gmail.com.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CNEye & ENT Hospital of Fudan University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recepteur d'origine nantais (RON) has been implicated in cell proliferation, metastasis, and chemoresistance of various human malignancies. The short-form RON (sf-RON) encoded by RON transcripts was overexpressed in gastric cancer tissues, but its regulatory functions remain illustrated. Here, we found that sf-RON promoted gastric cancer cell proliferation by enhancing glucose metabolism. Furthermore, sf-RON was proved to induce the β-catenin expression level through the AKT1/GSK3β signaling pathway. Meanwhile, the binding sites of β-catenin were identified in the promoter region of SIX1 and it was also demonstrated that β-catenin positively regulated SIX1 expression. SIX1 enhanced the promoter activity of key proteins in glucose metabolism, such as GLUT1 and LDHA. Results indicated that sf-RON regulated the cell proliferation and glucose metabolism of gastric cancer by participating in a sf-RON/β-catenin/SIX1 signaling axis and had significant implications for choosing the therapeutic target of gastric cancer.

Indexed as

AnimalsBase Sequencebeta CateninCell Line, TumorCell ProliferationDisease ProgressionGlucoseGlycolysisHomeodomain ProteinsHumansMaleMiceMice, Inbred BALB CMice, NudeReceptor Protein-Tyrosine KinasesSignal Transductionbeta CateninGlucoseHomeodomain ProteinsReceptor Protein-Tyrosine KinasesRON proteinSIX1 protein, humanGastric cancerGlucose metabolismsf-RONSIX1β-Catenin

Identifiers

PMID32399910
PMCPMC7851020
OpenAlexW3025431858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.